HIGHLIGHTS
- who: IMMUNOLOGY and collaborators from the (UNIVERSITY) have published the research work: Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting, in the Journal: (JOURNAL)
- what: The authors evaluate the real-world effect of omalizumab treatment on the use of OCS over a 2-year period. Consistent with the findings of Bousquet et_al , this study also indicated that asthma control (as reflected in OCS use) is improved to a greater extent among responders to omalizumab, compared with non-responders, and that these improvements (and the differences between . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.